Pharma BD Deal Intelligence
A $54B all-stock mega-merger that collapsed before it closed: AbbVie walked away in October 2014 the moment US Treasury tightened tax-inversion rules, eating a $1.635 billion breakup fee rather than losing the Ireland tax-domicile shift it was actually buying.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie and Shire agree on a $54 billion merger deal, with AbbVie paying about $54 billion in cash and stock to Shires shareholders in a tax inversion…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AbbVie agreed to acquire Shire in a $54 billion deal that would have moved AbbVie's tax domicile to Ireland. AbbVie terminated the deal in October 2014 after the US Treasury tightened tax inversion rules, paying Shire a $1.635 billion breakup fee.
AbbVie agreed to acquire Shire for ~$54B in July 2014 in a tax inversion deal. Terminated October 2014 after US Treasury tightened inversion rules. AbbVie paid $1.64B breakup fee. Shire later acquired by Takeda in 2019 for $62B.
AbbVie publicly stated the deal was strategically compelling beyond tax benefits but walked away within weeks of Treasury rule changes. Shire's rare disease portfolio ultimately went to Takeda.
AbbVie agreed to acquire Shire in a $54 billion deal that would have moved AbbVie's tax domicile to Ireland. AbbVie terminated the deal in October 2014 after the US Treasury tightened tax inversion rules, paying Shire a $1.635 billion breakup fee.
Deal terminated due to regulatory/tax policy changes. AbbVie Inc. abandoned the deal after US Treasury intervention.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Shire plc (this deal) | 2014 | $54.0B | 30 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2014 deals · AbbVie Inc. deals · Immunology deals